Corcept Therapeutics Incorporated (LON:0I3Q)

Market Cap	5.59B
Revenue (ttm)	539.20M
Net Income (ttm)	111.61M
Shares Out	n/a
EPS (ttm)	0.98
PE Ratio	50.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113
Average Volume	4,154
Open	74.25
Previous Close	71.02
Day's Range	71.47 - 74.40
52-Week Range	20.76 - 74.40
Beta	n/a
RSI	53.01
Earnings Date	May 2, 2025

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0I3Q

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD